<?xml version="1.0" encoding="UTF-8"?>
<list list-type="simple">
 <list-item>
  <p>
   <xref ref-type="sec" rid="toc1">
    <bold>1. Public health need for new tuberculosis vaccines and landscape analysis</bold>
   </xref>
  </p>
  <list list-type="simple">
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc1a">a. Introduction</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc1b">b. The WHO Global TB Programme</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc1c">c. The Value Proposition for TB Vaccines</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc1d">d. Overview of the tuberculosis vaccine clinical pipeline</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc1e">e. Modeling impact according to vaccine profile</xref>
    </p>
   </list-item>
  </list>
 </list-item>
 <list-item>
  <p>
   <xref ref-type="sec" rid="toc2">
    <bold>2. Vaccines for BCG replacement</bold>
   </xref>
  </p>
  <list list-type="simple">
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc2a">a. The BCG vaccine’s profile and role in public health</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc2b">b. VPM1002</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc2c">c. MTBVAC</xref>
    </p>
   </list-item>
  </list>
 </list-item>
 <list-item>
  <p>
   <xref ref-type="sec" rid="toc3">
    <bold>3. Vaccines for adolescents and adults (phase 2 and beyond)</bold>
   </xref>
  </p>
  <list list-type="simple">
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc3a">a. VPM1002</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc3b">b. M72/AS01E</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc3c">c. H56:IC31</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc3d">d. ID93/GLA-SE</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc3e">e. RUTI™ for Adjunctive Immunotherapy</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc3f">f. Vaccae™</xref>
    </p>
   </list-item>
  </list>
 </list-item>
 <list-item>
  <p>
   <xref ref-type="sec" rid="toc4">
    <bold>4. Diversifying TB vaccine platforms</bold>
   </xref>
  </p>
  <list list-type="simple">
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc4a">a. Importance of immune characterization</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc4b">b. Cytomegalovirus (CMV) recombinant vaccines against TB</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc4c">c. Novel emerging vaccine technologies: mRNA-based vaccines</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc4d">d. New candidates for live attenuated TB vaccines</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc4e">e. A systematic antigen discovery approach in humans</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc4f">f. Antibody-generating vaccines for TB</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc4g">g. Diverse T-Cell responses against 
      <italic>Mtb</italic>
     </xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc4h">h. Immune correlates and signatures of protection</xref>
    </p>
   </list-item>
  </list>
 </list-item>
 <list-item>
  <p>
   <xref ref-type="sec" rid="toc5">
    <bold>5. Use of models in translational TB vaccine research</bold>
   </xref>
  </p>
  <list list-type="simple">
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc5a">a. Small animal models</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc5b">b. The role of a continuous exposure natural transmission animal model for vaccine development</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc5c">c. Simian models of TB</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc5d">d. Achieving sterilizing immunity in animal challenge models</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc5e">e. Mucosal immunisation against TB</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc5f">f. Alternative routes of BCG immunization</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc5g">g. Progress in clinical use of a controlled human infection model (CHIM) for vaccine testing</xref>
    </p>
   </list-item>
  </list>
 </list-item>
 <list-item>
  <p>
   <xref ref-type="sec" rid="toc6">
    <bold>6. Perspectives from funders and global health organizations working on TB vaccines</bold>
   </xref>
  </p>
  <list list-type="simple">
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc6a">a. Perspectives from the Bill and Melinda Gates Foundation</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc6b">b. The Global TB Vaccine Partnership</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc6c">c. Aeras</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc6d">d. European and Developing Countries Clinical Trials Partnership</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc6e">e. The Stop TB Partnership, working group on new TB vaccines</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc6f">f. The Tuberculosis Vaccine Initiative</xref>
    </p>
   </list-item>
   <list-item>
    <p>
     <xref ref-type="sec" rid="toc6g">g. Proposed stage gate criteria for TB vaccines</xref>
    </p>
   </list-item>
  </list>
 </list-item>
 <list-item>
  <p>
   <xref ref-type="sec" rid="toc7">
    <bold>7. Conclusions</bold>
   </xref>
  </p>
 </list-item>
</list>
